Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

So as way of background, EZH2 is an epigenetic enzyme that's overexpressed in castrate-resistant prostate cancer, and it's ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

在非小细胞肺癌（NSCLC）患者中，原发 MET 扩增较为少见，且与不良预后相关[1]。随着 MET 抑制剂的问世和临床研究的不断探索，为原发 MET 扩增 NSCLC 患者带来了新的治疗希望。本期「In China For Global - MET ...

The locus coeruleus noradrenergic system could offer a promising avenue for treating insomnia with medication, especially in ...

Dr. Chris VanDeusen, Chief Scientific Officer, will present “TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Dermatologic Diseases,” ...